Gyre Reports Q2 2026 Revenue of $29.1 Million
Gyre Therapeutics reported strong sales for its commercial products ETUARY and Etorel, and affirmed 2026 revenue guidance of $100.5 to $111.0 million, though net loss widened.
View filing at SEC.gov →3 most recent filings and news items mentioning GYRE. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/GYRE/news?limit=20"
Pull GYRE filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayGyre Therapeutics reported strong sales for its commercial products ETUARY and Etorel, and affirmed 2026 revenue guidance of $100.5 to $111.0 million, though net loss widened.
View filing at SEC.gov →Gyre Therapeutics announced the appointment of CEO Yue Xiong and veterans Maxwell Kirkby and Claire Weston to its board, effective August 1, 2026. This expansion of scientific and governance expertise is intended to bolster Gyre's cross-border drug development efforts and strengt
View filing at SEC.gov →Gyre Therapeutics filed an 8-K with a presentation outlining its fully-integrated biopharmaceutical platform combining operations with Cullgen Inc., featuring multiple product candidates across fibrosis, inflammatory and oncology indications. The filing details clinical developme
View filing at SEC.gov →